Summary
Biogen Idec Inc. (BIIB) filed an 8-K on May 4, 2009, primarily to report on the post-employment arrangements for its former Chief Operating Officer, Hans Peter Hasler. The company has entered into a consulting agreement with a subsidiary through which Mr. Hasler will provide management services. This agreement underscores the company's strategy to retain valuable expertise during transitional periods, ensuring continuity and knowledge transfer. Investors should note that while Mr. Hasler is no longer a named executive officer in a primary role, his continued engagement in a consulting capacity suggests his insights remain important to the company's operations. The compensation structure, involving Swiss francs, indicates the international scope of operations or specific contractual terms. This filing is significant as it provides transparency regarding the separation and subsequent engagement of a key executive. The initial term of the consulting agreement runs from May 1, 2009, to December 31, 2009, with provisions for continuation thereafter. In addition to consulting, Mr. Hasler will also assume the role of Chairman of the Board for the subsidiary. This arrangement is likely intended to mitigate any disruption caused by his departure from the COO role and to leverage his experience in a more focused capacity. The financial terms, including a consulting fee and director's fee, are detailed, offering clarity on the costs associated with this arrangement.
Key Highlights
- 1Former COO Hans Peter Hasler enters into a consulting agreement with a Biogen Idec subsidiary.
- 2The agreement is for management services and has an initial term from May 1, 2009, to December 31, 2009.
- 3Mr. Hasler will receive 154,000 Swiss francs for his consulting services during the initial term.
- 4Mr. Hasler will also serve as Chairman of the Board for the subsidiary, receiving an annual director's fee of 10,000 Swiss francs.
- 5The consulting agreement includes provisions for termination by either party after the initial term.
- 6The filing addresses executive departures and subsequent arrangements, providing transparency for investors.